abstract
OBJECTIVE:
Hormone therapy (HT) alleviates menopausal symptoms, but there is a lack of consensus regarding its use among premenopausal ovarian cancer survivors.
METHODS:
We
systematically reviewed the literature and searched the Medline
(1966-2014), Scopus (2004-2014), Popline (1974-2014), ClinicalTrials.gov
(2008-2014), and Cochrane Central Register of Controlled Trials CENTRAL
(1999-2014) databases and the reference lists of electronically
retrieved studies. Statistical meta-analysis was performed using RevMan
5.1 software.
RESULTS:
Six
studies were included in our systematic review, which involved 1,521
women. Among them, 451 women (29.6%) received HT, whereas the remaining
1,070 women (70.4%) did not receive any treatment. We noticed a
statistically significant reduction of ovarian cancer-related
deaths among women who received HT (odds ratio, 0.47; 95% CI,
0.28-0.80); however, disease recurrence rates did not differ between the
two groups (odds ratio, 0.71; 95% CI, 0.45-1.14). Studies included in
the present systematic review did not report a significant difference in
overall survival and disease-free survival rates among women receiving
HT and controls.
CONCLUSIONS:
Based on the results of meta-analysis, HT does not influence the odds of ovarian cancer
recurrence; however, this conclusion must be confirmed separately
because of significant limitations in the methodological quality of the
studies included.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.